Evidence map›Paper›PMID 34471125›Full record

ArticleNature communications2021

Structure of the human marker of self 5-transmembrane receptor CD47.

Gustavo Fenalti, Nicolas Villanueva, Mark Griffith, Barbra Pagarigan, Sirish Kaushik Lakkaraju, Richard Y-C Huang, Nadia Ladygina, Alok Sharma, David Mikolon, Mahan Abbasian and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Tolerating CD47.Clinical and translational medicine · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Gustavo FenaltiMolecular Structure and Design, Bristol Myers Squibb, San Diego, CA, USA. Gustavo.Fenalti@bms.com.ORCID 0000-0001-6554-2351
Nicolas VillanuevaMolecular Structure and Design, Bristol Myers Squibb, San Diego, CA, USA.
Mark GriffithProtein Homeostasis, Bristol Myers Squibb, San Diego, CA, USA.
Barbra PagariganMolecular Structure and Design, Bristol Myers Squibb, San Diego, CA, USA.
Sirish Kaushik LakkarajuMolecular Structure and Design, Bristol Myers Squibb, Princeton, NJ, USA.
Richard Y-C HuangPharmaceutical Candidate Optimization, Nonclinical Research and Development, Bristol Myers Squibb, Princeton, NJ, USA.
Nadia LadyginaPharmacology, Bristol Myers Squibb, San Diego, CA, USA.
Alok SharmaMolecular Structure and Design, Bristol Myers Squibb, Princeton, NJ, USA.
David MikolonDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Mahan AbbasianDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Jeffrey JohnsonDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Haralambos HadjivassiliouDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Dan ZhuDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Philip P ChamberlainProtein Homeostasis, Bristol Myers Squibb, San Diego, CA, USA.ORCID 0000-0002-6407-7344
Ho ChoDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Kandasamy HariharanDiscovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Bristol-Myers Squibb (United States) · USBristol-Myers Squibb (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD47 is the only 5-transmembrane (5-TM) spanning receptor of the immune system. Its extracellular domain (ECD) is a cell surface marker of self that binds SIRPα and inhibits macrophage phagocytosis, and cancer immuno-therapy approaches in clinical trials are focused on blocking CD47/SIRPα interaction. We present the crystal structure of full length CD47 bound to the function-blocking antibody B6H12. CD47 ECD is tethered to the TM domain via a six-residue peptide linker (

Indexed as

BiomarkersAntibodies, BlockingAntigens, DifferentiationBinding SitesCarrier ProteinsCD47 AntigenHumansMacrophagesModels, MolecularPhagocytosisReceptors, ImmunologicSignal TransductionAntibodies, BlockingAntigens, DifferentiationBiomarkersCarrier ProteinsCD47 AntigenCD47 protein, humanReceptors, Immunologic

Identifiers

PMID34471125
PMCPMC8410850
OpenAlexW3197102703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.